珍宝岛 (603567)
HeiLongJiang ZBD Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 94099.65
- Circulating A-Shares(W): 93954.05
- Earnings Per Share(RMB): -0.3969
- Net Assets Per Share(RMB): 7.7453
- Operating Revenue(W RMB): 91818.60
- Total Profit(W RMB): -46494.71
- **Net Profit Attributable to Parent(W RMB) **: -37309.83
- Net Profit Growth Rate(%): -193.81
- Weighted Return on Equity(%): -4.9000
- Operating Cash Flow Per Share(RMB): 0.2370
- Undistributed Profit Per Share(RMB): 3.7668
- Capital Reserve Per Share(RMB): 2.4850
2. Main Business
The main business covers:
- Planting of Chinese medicinal herbs
- Trading of Chinese medicinal herbs
- New drug development
- Manufacturing
- Marketing to centralized drug distribution and e-commerce
3. Company Basic Information
- Company Name: Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Listing Date: 2015-04-24
- Industry: Pharmaceutical Manufacturing
- Address: No. 8 Yantai Road, Pingfang District, Harbin City, Heilongjiang Province
- Website: https://www.zbdzy.com
- Company Profile: The company's predecessor was Heilongjiang Province ZBD Pharmaceutical Co., Ltd. ZBD Co., Ltd. was legally transformed into Heilongjiang ZBD Pharmaceutical Co., Ltd. on March 17, 2011, and registered with the Jixi City Administration for Market Regulation in Heilongjiang Province. The business license registration number is: 230322100000050.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Heilongjiang Chuangda Group Co., Ltd. | Corporate Entity | 47098.53 | 50.13 |
| 2 | Heilongjiang Chuangda Group Co., Ltd. - Pledged Special Account for 2023 Privately Placed Exchangeable Corporate Bonds (Phase I) to Professional Investors | Asset Management Plan | 8477.30 | 9.02 |
| 3 | Bozhou Junze Fanglong Equity Investment Center (Limited Partnership) | Corporate Entity | 4839.82 | 5.15 |
| 4 | Huzhou Saihan Equity Investment Partnership (Limited Partnership) | Corporate Entity | 4704.98 | 5.01 |
| 5 | Shanghai Shengzhong Investment Management Co., Ltd. - Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund Partnership (Limited Partnership) | Asset Management Plan | 1106.91 | 1.18 |
| 6 | Heilongjiang Chuangda Group Co., Ltd. - Pledged Special Account for 2023 Privately Placed Exchangeable Corporate Bonds (Phase II) to Professional Investors | Asset Management Plan | 757.61 | 0.81 |
5. Concept Sectors
- Generic Drugs
- Innovative Drugs
- AI Healthcare
- Margin Trading & Securities Lending
- Major Shareholder Reduction
- Risk Warning
- High Pledged Shares
- Low Safety Score
- SSE 580
Remarks
- Data update date: 2025-10-31
- Data source: Public market information